StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3044% below fair value
$2.88−0.15 (-4.95%)

Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –

Protalix BioTherapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Protalix BioTherapeutics's pe ratio was 13.6× on Nov 11, 2026, against 38.8× a year earlier. Over the last 4 years it ranged from 0.9× to 155.0×, with a median of 18.1×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202613.6×−31.4
2025Dec 31, 202545.0×+23.4
2024Jul 31, 202421.6×−14.0
2023Dec 29, 202335.6×+34.3
2017Jan 31, 20171.3×+0.4
2016Dec 30, 20161.0×–

More Protalix BioTherapeutics figures

See a number that looks wrong?